Inflammatory Signal Inhibitors for COVID-19 (MATIS) (MATIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04581954

Recruitment Status : Unknown

Verified June 2022 by Imperial College London.
Recruitment status was: Recruiting

First Posted : October 9, 2020

Last Update Posted : July 1, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Imperial College Healthcare NHS Trust

Rigel Pharmaceuticals

Novartis

Information provided by (Responsible Party):

Imperial College London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 30, 2022
Estimated Study Completion Date :	June 30, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z.

To Top